Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 676-678

  Moser, Christian ^a   Pohl, Gudrun ^b   Haslinger, Isabella ^c   Knapp, Sylvia ^c   Rowczenio, Dorota ^d   Russel, Tonia ^d   Lachmann, Helen J ^d   Lang, Ursula ^a   Kovarik, Josef ^a  

^a Wilhelminenspital   (Austria)

^b 1st Medical Department with Oncology   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Anakinra; Colchicine; Familial Mediterranean fever; Interleukin 1 receptor antagonist

Indexed keywords

COLCHICINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AMYLOIDOSIS; ARTICLE; CASE REPORT; CONGENITAL NEPHROTIC SYNDROME; DRUG EFFICACY; DRUG SAFETY; FAMILIAL MEDITERRANEAN FEVER; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEINURIA;

AMYLOIDOSIS; COLCHICINE; DRUG RESISTANCE; FAMILIAL MEDITERRANEAN FEVER; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 58449114163     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn646     Document Type: Article

References (10)

1. Langevitz P, Livneh A. Third International Conference on Familial Mediterranean Fever and Other Hereditary Inflammatory Disorders. Isr Med Assoc J 2003; 5: 148-150
2. Chae JJ, Wood G, Masters SL et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate Il-1-beta production. Proc Natl Acad Sci 2006; 103: 9982-9987
3. Lachmannn HJ, Sengul B, Yavuzsen TU et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45: 746-750
4. Gershoni-Baruch R, Brik R, Zacks N et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003; 48: 1149-1155
5. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet 2001; 9: 473-483
6. Cerquaglia C, Diaco M, Nucera G et al. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy 2005; 4: 117-124
7. Knecht A, de Beer FC, Pras M. Serum amyloid A protein in familial Mediterranean fever. Ann Intern Med 1985; 102: 71-72
8. Klimecki WT, Futscher BW, Grogan TM et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-2458
9. Dvorak Z, Modriansky M, Pichard-Garcia L et al. Colchicine downregulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol 2003; 64: 160-169
10. Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol 2006; 18: 108-117